MARKET

ALDX

ALDX

Aldeyra
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.48
+0.43
+3.57%
After Hours: 12.48 0 0.00% 17:51 05/07 EDT
OPEN
12.43
PREV CLOSE
12.05
HIGH
12.74
LOW
12.21
VOLUME
1.32M
TURNOVER
--
52 WEEK HIGH
15.95
52 WEEK LOW
2.730
MARKET CAP
609.28M
P/E (TTM)
-11.2009
1D
5D
1M
3M
1Y
5Y
The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders have taken advantage of initial public offerings. A couple of chief executive officers were among the insiders ...
Benzinga · 20h ago
Aldeyra Therapeutics (ALDX) Receives a Buy from Alliance Global Partners
Alliance Global Partners analyst Matthew Cross maintained a Buy rating on Aldeyra Therapeutics (ALDX) today and set a price target of $32.00. The
SmarterAnalyst · 1d ago
Aldeyra Therapeutics (ALDX) Received its Third Buy in a Row
After Leerink Partners and Oppenheimer gave Aldeyra Therapeutics (NASDAQ: ALDX) a Buy rating last month, the company received another Buy, this time from
SmarterAnalyst · 2d ago
DJ Aldeyra Therapeutics, Inc. CEO Todd Brady on Q1 2021 Results -- Earnings Call Transcript >ALDX
Dow Jones · 2d ago
Aldeyra Therapeutics (ALDX) Gets a Buy Rating from H.C. Wainwright
In a report released today, Edwin Zhang from H.C. Wainwright reiterated a Buy rating on Aldeyra Therapeutics (ALDX), with a price target of $26.00. The
SmarterAnalyst · 2d ago
JonesTrading Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)
JonesTrading analyst Prakhar Agrawal reiterated a Buy rating on Aldeyra Therapeutics (ALDX) today. The company's shares closed last Thursday at $11.92.
SmarterAnalyst · 2d ago
Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today reported financial results fo...
Business Wire · 3d ago
Aldeyra Therapeutics Q1 EPS $(0.25) Beats $(0.27) Estimate
Aldeyra Therapeutics (NASDAQ:ALDX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 26.47 percent increase over losses of $(0.34) per share
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALDX. Analyze the recent business situations of Aldeyra through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALDX stock price target is 25.67 with a high estimate of 32.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 24.32M
% Owned: 49.82%
Shares Outstanding: 48.82M
TypeInstitutionsShares
Increased
28
1.69M
New
24
715.02K
Decreased
24
2.92M
Sold Out
12
807.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Richard Douglas
President/Chief Executive Officer/Director
Todd Brady
Chief Financial Officer
Joshua Reed
Senior Vice President
James Gow
Senior Vice President
Stephen Machatha
Other
David McMullin
Independent Director
Ben Bronstein
Independent Director
Martin Joyce
Independent Director
Nancy Miller-rich
Independent Director
Gary Phillips
Independent Director
Neal Walker
No Data
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.

Webull offers kinds of Aldeyra Therapeutics Inc stock information, including NASDAQ:ALDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALDX stock methods without spending real money on the virtual paper trading platform.